First Time Loading...

Roivant Sciences Ltd
NASDAQ:ROIV

Watchlist Manager
Roivant Sciences Ltd Logo
Roivant Sciences Ltd
NASDAQ:ROIV
Watchlist
Price: 10.84 USD 7.54% Market Closed
Updated: Mar 28, 2024

Intrinsic Value

ROIV's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Roivant Sciences Ltd. engages in the biopharmaceutical business, which develops drug candidates Vants in subsidiary companies. [ Read More ]

The intrinsic value of one ROIV stock under the Base Case scenario is 1.19 USD. Compared to the current market price of 10.84 USD, Roivant Sciences Ltd is Overvalued by 89%.

Key Points:
ROIV Intrinsic Value
Base Case
1.19 USD
Overvaluation 89%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Roivant Sciences Ltd

Backtest ROIV Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling ROIV stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

How can I assist you today?

Provide an overview
of Roivant Sciences Ltd's business.

What risks and challenges
does Roivant Sciences Ltd face in the near future?

Summarize the latest earnings report
of Roivant Sciences Ltd.

Provide P/E
for Roivant Sciences Ltd and its competitors.

Financials

Balance Sheet Decomposition
Roivant Sciences Ltd

Current Assets 6.8B
Cash & Short-Term Investments 6.7B
Receivables 44.3m
Other Current Assets 91.6m
Non-Current Assets 505.9m
Long-Term Investments 239.9m
PP&E 68.8m
Intangibles 150.4m
Other Non-Current Assets 46.8m
Current Liabilities 244.9m
Accounts Payable 35.2m
Accrued Liabilities 132.6m
Other Current Liabilities 77m
Non-Current Liabilities 978m
Long-Term Debt 403.3m
Other Non-Current Liabilities 574.7m
Efficiency

Earnings Waterfall
Roivant Sciences Ltd

Revenue
123.2m USD
Cost of Revenue
-15.3m USD
Gross Profit
107.9m USD
Operating Expenses
-1.2B USD
Operating Income
-1.1B USD
Other Expenses
5.5B USD
Net Income
4.5B USD

Free Cash Flow Analysis
Roivant Sciences Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

ROIV Profitability Score
Profitability Due Diligence

Roivant Sciences Ltd's profitability score is 35/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional Revenue Growth Forecast
Exceptional ROE
Exceptional 1-Year Revenue Growth
35/100
Profitability
Score

Roivant Sciences Ltd's profitability score is 35/100. The higher the profitability score, the more profitable the company is.

ROIV Solvency Score
Solvency Due Diligence

Roivant Sciences Ltd's solvency score is 83/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Negative Net Debt
Low D/E
83/100
Solvency
Score

Roivant Sciences Ltd's solvency score is 83/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ROIV Price Targets Summary
Roivant Sciences Ltd

Wall Street analysts forecast ROIV stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ROIV is 16.15 USD with a low forecast of 12.12 USD and a high forecast of 24.15 USD.

Lowest
Price Target
12.12 USD
12% Upside
Average
Price Target
16.15 USD
49% Upside
Highest
Price Target
24.15 USD
123% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

ROIV Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

ROIV Price
Roivant Sciences Ltd

1M 1M
-7%
6M 6M
-14%
1Y 1Y
+47%
3Y 3Y
+10%
5Y 5Y
+4%
10Y 10Y
+4%
Annual Price Range
10.84
52w Low
7.09
52w High
13.19
Price Metrics
Average Annual Return -10.87%
Standard Deviation of Annual Returns 14.7%
Max Drawdown -79%
Shares Statistics
Market Capitalization 8.7B USD
Shares Outstanding 805 850 000
Percentage of Shares Shorted 6.44%

ROIV Return Decomposition
Main factors of price return

What is price return decomposition?

ROIV News

Last Important Events
Roivant Sciences Ltd

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Roivant Sciences Ltd

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Roivant Sciences Ltd Logo
Roivant Sciences Ltd

Country

Bermuda

Industry

Pharmaceuticals

Market Cap

8.7B USD

Dividend Yield

0%

Description

Roivant Sciences Ltd. engages in the biopharmaceutical business, which develops drug candidates Vants in subsidiary companies. The Company, through its subsidiaries, is focused on delivering medicines and technologies to patients. The firm builds biotech and healthcare technology companies (Vants) and deploys technology to drive research and development and commercialization. Its drug discovery capabilities include a computational physics-based platform for in silico drug design and machine learning-based models for protein degradation. Its development-stage product candidates include Tapinarof, Cerdulatinib, IMVT-1401, ARU-1801, Namilumab, LSVT-1701, Cerdulatinib, DMVT-504, DMVT-503, ARU-2801, AFM32 and CVT-TCR-01. Its Vant family includes Dermavant, Immunovant, Aruvant, Proteovant, Lysovant, Kinevant, Affivant, Cytovant, Arbutus, Sio Gene Therapies, Genevant, Silicon Therapeutics, VantAI, Lokavant, Datavant and Alyvant.

Contact

London
Suite 1, 3rd Floor, 11-12 St. James's Square
+442074003347.0
http://roivant.com/

IPO

2020-12-03

Employees

665

Officers

CEO & Director
Mr. Matthew Gline
President & COO
Dr. Eric Venker M.D., Pharm.D.
President, Chief Investment Officer & Director
Dr. Mayukh Sukhatme M.D.
Chief Financial Officer
Mr. Richard Pulik
Chief Accounting Officer
Ms. Rakhi Kumar
Chief Technology Officer
Dr. Huafeng Xu Ph.D.
Show More
General Counsel
Mr. Josh Chen
Head of People
Ms. Kelly Graff
Head of Global Transactions & Risk Management
Ms. Marianne L. Romeo
Executive Vice President of Roivant Health
Mr. Alex Gasner
Show Less

See Also

Discover More
What is the Intrinsic Value of one ROIV stock?

The intrinsic value of one ROIV stock under the Base Case scenario is 1.19 USD.

Is ROIV stock undervalued or overvalued?

Compared to the current market price of 10.84 USD, Roivant Sciences Ltd is Overvalued by 89%.